Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Edema and NRAS[original query] |
---|
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67. Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha |
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Apr 18 (7): 2056-65. Hayes D Neil, Lucas Amy S, Tanvetyanon Tawee, Krzyzanowska Monika K, Chung Christine H, Murphy Barbara A, Gilbert Jill, Mehra Ranee, Moore Dominic T, Sheikh Arif, Hoskins Janelle, Hayward Michele C, Zhao Ni, O'Connor Wendi, Weck Karen E, Cohen Roger B, Cohen Ezra E |
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 3 28 (14): 3002-3010. Schuler Martin, Zimmer Lisa, Kim Kevin B, Sosman Jeffrey A, Ascierto Paolo A, Postow Michael A, De Vos Filip Y F L, van Herpen Carla M L, Carlino Matteo S, Johnson Douglas B, Berking Carola, Reddy Micaela B, Harney Allison S, Berlin Jordan D, Amaria Rodabe |
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. BMC medicine 2023 1 21 (1): 2. Wang Xuan, Luo Zhiguo, Chen Jing, Chen Yu, Ji Dongmei, Fan Li, Chen Ling, Zhao Qian, Hu Pei, Sun Peng, Jia Zhongwei, Guo Jun, Si |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: